ROIV — Roivant Sciences Ltd

Roivant Sciences Ltd (ROIV) is a biotechnology company listed on NASDAQ. It is led by Matthew Gline, based in 50 Broadway, London, United Kingdom, SW1H 0DB, with about 750 employees. Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, the United Kingdom.

Latest reported ROIV revenue for 2025-09-30 was $1.6M. Net income was -$166.0M. Revenue was down 27.6% from 2025-06-30 to 2025-09-30. ROIV currently screens at market cap $7.47B.

Use this ROIV page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ROIV quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ROIV SEC filings page. Lician reads the product cache first so this HTML stays unique to Roivant Sciences Ltd even when a live quote feed is slow.